Aquestive is a pharmaceutical company aiming to solve patients’ problems by advancing current standards of care through simplifying complex delivery methods. Aquestive is developing orally administered products to provide novel alternatives to invasive and inconvenient standard of care therapies. Our focus is to improve medications and outcomes for patients with central nervous system (CNS) conditions and severe allergies, including anaphylaxis.
Access a comprehensive collection of financial information about Aquestive. Download current and previous SEC filings, including earnings releases, and quarterly and annual reports.
Join upcoming meetings and listen to past sessions that review the Aquestive business landscape, including sales performance and objectives, product-development activities, and the status of strategic partnerships.
PharmFilm® technology and Aquestive's development expertise has created a robust, proprietary CNS and complex molecule portfolio. See the expanding collection of medicines designed to overcome barriers that the patients face.